Trial Information

Summary: A Phase I Study of SSR244738 (TED5799) in Patients with Refractory Solid Tumors

The purpose of the study is to determine the maximum dose of SSR244738 based on side effects in patients participating in the study and through pharmacokinetics. Pharmacokinetics (PKs) is a way to determine the levels of SSR244738 in the blood and to study how the body absorbs, distributes, metabolizes, and eliminates the drug. This is done through frequent blood sampling on key days during the first 4 weeks of treatment.

SSR244738 is an antimitotic, antineoplastic, chemotherapeutic agent that works by blocking the cell cycle at the G2 checkpoint and blocking the process of mitoses. It is not approved by the FDA and is an investigational drug.

Patient Inclusion Criteria:

• Solid tumor that has not responded to other therapy or for which no reasonable therapy exists

Not all eligibility criteria are listed. Additional criteria must be met to be eligible.

Patient Exclusion Criteria:

• > 5 prior chemotherapy regimens
• History of cardiovascular disease
• History of bone marrow transplant

If you would like to learn more about participating in this study, please send an e-mail message using the form below.